

ImmuPharma PLC  
("ImmuPharma" or the "Company")

**Publication of Information Note  
In advance to admission to trading on Euronext Growth Brussels**

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, is pleased to announce that, further to the announcement of 13 December 2019, that its shares will be admitted to trading on Euronext Growth Brussels ("Euronext") under ticker 'ALIMM', it has today published the Information Note, as required by the Euronext Growth Market Rules Book and Belgian financial regulations.

The Information Note is available on ImmuPharma's website [www.immupharma.co.uk](http://www.immupharma.co.uk). Attention is drawn to certain financial information on a period subsequent to that notified in our Interim Results which is included in Parts II and IV of the Information Note which is notifiable under AIM Rule 11. This information is set out in the Appendix below.

Admission to Euronext is expected to take effect from 19 December 2019. This new listing does not affect the trading of ImmuPharma's shares on AIM, nor is there any intention from the Company to raise additional funds from either AIM or Euronext.

The dual listing on Euronext Growth Brussels aims to further increase the visibility of ImmuPharma's shares in continental Europe and with European investors, following the Company's recent deal with Avion Pharmaceuticals, who are now funding an international Phase III trial for the lead programme, Lupuzor™. The investment thesis for ImmuPharma and specifically Lupuzor™ has been repositioned and the Company looks forward to providing further progress updates on the Phase III program with Avion, as well as entering into additional partnerships outside of the US.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

For further information please contact:

<b>ImmuPharma PLC</b> ( <a href="http://www.immupharma.com">www.immupharma.com</a> )	+ 44 (0) 207 152 4080
Tim McCarthy, Chairman	
Dimitri Dimitriou, Chief Executive Officer	
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
<b>SPARK Advisory Partners Limited (NOMAD)</b>	+44 (0) 203 368 8974
Neil Baldwin	
Vassil Kirtchev	
<b>Stanford Capital Partners (Joint Broker)</b>	+44 (0) 203 815 8880
Patrick Claridge, John Howes	
<b>SI Capital (Joint Broker)</b>	+44 (0) 1483 413500
Nick Emerson	
<b>4Reliance (Euronext Growth Listing Sponsor)</b>	+32 (0) 2777 00560
Jean-Charles Snoy	

**Degroof Petercam (Liquidity Provider)**

Erik De Clippel

+32 (0) 2 287 95 34

+32 (0) 477 504 784

+32 (0) 497 50 84 03

**Backstage Communication**

Olivier Duquaine

+32 (0) 477 504 784

Jean-Louis Dubrulle

+32 (0) 497 50 84 03

**Notes to Editors****About ImmuPharma PLC**

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 29 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US. For additional information about ImmuPharma please visit [www.immupharma.com](http://www.immupharma.com).

**About Avion Pharmaceuticals**

Avion Pharmaceuticals, LLC is a US-based specialty pharmaceutical company formed to develop, acquire and market a portfolio of innovative pharmaceutical products in the Women's Health and other therapeutic categories aligned with our mission to improve the quality of patient lives. Avion Pharmaceuticals focuses on identifying opportunities to develop, acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfil unmet medical needs. For additional information about Avion Pharmaceuticals, visit [www.avionrx.com](http://www.avionrx.com).

**About Lupuzor™ and Lupus**

Lupuzor™ is ImmuPharma's lead compound, a peptide therapeutic and a first-in class autophagy immunomodulator for systemic lupus erythematosus (SLE or lupus) a potentially life-threatening auto-immune disease. Lupus is a chronic inflammatory disease which is thought to affect some 5 million individuals worldwide. The current standard of care still consists of drugs which have many side-effects and limited efficacy. Despite the need for an effective treatment, only one new therapy, namely GlaxoSmithKline's Benlysta, has been approved to treat the condition over the past 50 years. As such, there clearly exists an unmet medical need for a drug that has a strong efficacy and safety profile.

## Appendix

### CONSOLIDATED STATEMENT OF CASHFLOWS FOR THE PERIOD ENDED 30 SEPTEMBER 2019

	Unaudited 9 months ended 30 September 2019 £	Audited Year ended 31 December 2018 £
<b>Cash flows from operating activities</b>		
Cash used in operations	(2,549,281)	(5,606,138)
Taxation	(543,668)	889,787
Interest paid	(3,208)	(4,783)
Net cash used in operating activities	<u>(3,096,157)</u>	<u>(4,721,134)</u>
<b>Investing activities</b>		
Purchase of property plant and equipment	(6,003)	(102,880)
Purchase of investments	-	(2,000,000)
Interest received	4,986	12,491
Net cash used in investing activities	<u>(1,017)</u>	<u>(2,090,389)</u>
<b>Financing activities</b>		
(Decrease)/increase in bank overdraft	(253)	(72)
Loan repayments	(68,861)	(138,809)
Settlements from Sharing agreement	74,901	-
Gross proceeds from issue of new share capital	-	10,000,000
Share capital issue costs	-	(713,929)
Net cash generated from/ (used in) financing activities	<u>5,787</u>	<u>9,147,190</u>
Net increase/(decrease) in cash and cash equivalents	(3,091,387)	2,335,667
Cash and cash equivalents at beginning of year	4,911,448	2,729,468
Effects of exchange rates on cash and cash equivalents	180,367	(153,687)
<b>Cash and cash equivalents at period end</b>	<u><u>2,000,428</u></u>	<u><u>4,911,448</u></u>

### *Capitalisation and Indebtedness Statement*

The following is the consolidated unaudited statement of Capitalisation and Indebtedness  
as of 30 September 2019

Current liabilities		
Financial borrowings	£	51,949
Trade and other payables	£	277,262
<b>Total current liabilities</b>	<u>£</u>	<u>329,211</u>
<b>Non current liabilities</b>	£	-
Equity		
Ordinary shares	£	13,946,744

Share premium	£ 27,320,145
Merger reserve	£ 106,148
Other reserves	£ 3,157,963
Retained earnings	<u>-£ 38,040,631</u>
<b>Total equity</b>	<b><u>£ 6,490,369</u></b>

The Company liabilities are all unsecured and not guaranteed by collateral.